Background: Essential hypertension is a common clinical disease and a risk factor for cardiovascular and cerebrovascular diseases. Olmesartan medoxomil, amlodipine, and hydrochlorothiazide are commonly used antihypertensive drugs. The aim of this study was to establish a robust UPLC-MS/MS method for the simultaneous determination of olmesartan medoxomil, amlodipine, and hydrochlorothiazide in dog plasma. At the same time, the and release studies were conducted, and a preliminary correlation (IVIVC) evaluation was performed.
Methods: The bioequivalence experiment was conducted with a double-crossed design. Three major components were extracted and analyzed by UHPLC-MS/MS. With the MRM scan, olmesartan and amlodipine were quantified by fragment conversion (m/z 447.10→190.10) and (m/z 408.95→294.00) under positive ESI mode, while hydrochlorothiazide was quantified with fragment conversion (m/z 295.90→268.90) under negative ESI mode. The release studies were performed using a USP paddle, and the dissolution medium was chosen from pH 6.0 to pH 6.8 according to the BCS classification of compounds. The IVIVC was calculated using the Wagner-Nelson equation.
Results: The linear ranges of olmesartan, amlodipine, and hydrochlorothiazide in the plasma were 5.0-2500, 0.1-50, and 3.0-1500 ng/mL, respectively. All accuracies were within 3.8% of the target values, and the findings revealed that intra-day and inter-day accuracies were less than 12.1%. Moreover, the recoveries exceeded 88.3%, the matrix effect tests were positive, and the stability tests were positive. With the establishment of correlation, the distinguishable dissolution condition (pH 6.8) was selected as the predictable condition.
Conclusion: The established method was suitable for the preclinical pharmacokinetic study of tripartite drugs with strong specificity and high sensitivity. Through the evaluation of IVIVC, the connection between in vivo and drug testing was initially established.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0113816128295265240613061905 | DOI Listing |
Spectrochim Acta A Mol Biomol Spectrosc
January 2025
Department of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran. Electronic address:
The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.
View Article and Find Full Text PDFAm Surg
December 2024
Kaiser Permanente Northwest, Portland, OR, USA.
Background: High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States.
View Article and Find Full Text PDFChemosphere
February 2025
Department of Chemistry, Soongsil University, Seoul, 06978, South Korea; Department of Sustainable Engineering, Saveetha School of Engineering, SIMATS, Chennai, 602105, India; Department of Chemical Engineering, Quchan University of Technology, Quchan, Iran.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).
View Article and Find Full Text PDFFront Pharmacol
October 2024
Department of Rehabilitation, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Hypertension is a common risk factor for cardiovascular disease. Pharmacogenomics, as a tool for personalized healthcare, helps in determining the optimal drug treatment based on the genome of individual patient. This study reports a 49-year-old male with acute cerebral infarction, pulmonary infection, extremely high-risk hypertension (grade3), type 2 diabetes, hyperhomocysteinemia, hyperlipidemia, and fatty liver.
View Article and Find Full Text PDFMed Clin (Barc)
December 2024
Centre for Research on Drug Safety (CESME), Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, University of Valladolid (Centro de Estudios Sobre la Seguridad de los Medicamentos (CESME), Departamento de Biología Celular, Histología, Farmacología y Genética, Facultad de Medicina, Universidad de Valladolid), Valladolid, Spain; Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid (GIR Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología, Universidad de Valladolid), Spain. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!